Table 1.

Specificity and coordinate effects of PD169616- and β -PMA-induced inhibition of SERT activity in rat midbrain synaptosomes

Treatments	SERT activity (% control)	Percentage of inhibition
Vehicle	100.00 ± 0.05	0.00
PD169316	64.78 ± 3.00	35.22^a
β-PMA	74.95 ± 2.16	25.05^a
PD169316 plus β-PMA	47.16 ± 1.98	52.84^a^,^b
Staurosporine	97.26 ± 3.90	2.74^c
Staurosporine plus PD169316	59.78 ± 3.30	40.22^a
Staurosporine plus β-PMA	98.01 ± 2.64	1.99^c
Staurosporine plus PD169316 plus β-PMA	63.95 ± 3.16	36.05^a^,^d
BIM I	102.26 ± 1.25	0.00^c
BIM I plus PD169316	53.78 ± 1.29	46.22^a
BIM I plus β-PMA	102.99 ± 5.84	0.00^c
BIM I plus PD169316 plus β-PMA	69.05 ± 4.23	30.95^a^,^d

Purified rat midbrain synaptosomes were preincubated for 30 min at 37°C in the absence (vehicle) or presence of the following agents: PD169316, 10 μm; β-PMA, 1 μm; bisindolylmaleimide I, 500 nm; and staurosporine, 2.5 μm. Protein kinase C inhibitor staurosporine and BIM I were added 20 min before the addition of PD169316, β-PMA, or both. 5-HT uptake was performed as described in Materials and Methods. Experiments were conducted in triplicate, and the mean values ± SEM from three independent experiments are given. Significant differences were determined by one-way ANOVA with a Tukey-Kramer post hoc test.
↵ a Significantly different from levels observed under vehicle conditions; p < 0.01.
↵ b Significantly different from the levels observed with the application of single modulator (PD169316 or β-PMA); p < 0.05.
↵ c Not statistically different from the levels observed under vehicle conditions.
↵ d Significantly different from the levels observed with coapplication of PD169316 and β-PMA; p < 0.05.